In support of this concept, low levels of DCN in cancers are associated with significantly poorer outcome and a shorter time to progression than with patients expressing higher levels of DCN in breast, lung, and soft tissue cancers as well as in myeloma [21–23, 28]. Here, DCN is linked to cancer.